Rowlandmiller & PARTNERS.ADV Has $114,000 Stock Position in Baxter International Inc. (NYSE:BAX)

Rowlandmiller & PARTNERS.ADV trimmed its stake in shares of Baxter International Inc. (NYSE:BAX) by 18.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,323 shares of the medical instruments supplier’s stock after selling 744 shares during the quarter. Rowlandmiller & PARTNERS.ADV’s holdings in Baxter International were worth $114,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Baxter International by 1.9% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,160,666 shares of the medical instruments supplier’s stock valued at $33,845,000 after acquiring an additional 21,592 shares during the last quarter. Nicholas Hoffman & Company LLC. bought a new position in Baxter International in the 4th quarter worth approximately $907,000. Bank of New York Mellon Corp raised its position in Baxter International by 22.3% in the 4th quarter. Bank of New York Mellon Corp now owns 15,359,040 shares of the medical instruments supplier’s stock worth $447,870,000 after purchasing an additional 2,803,920 shares during the last quarter. Dodge & Cox raised its position in Baxter International by 13.0% in the 4th quarter. Dodge & Cox now owns 50,377,294 shares of the medical instruments supplier’s stock worth $1,469,002,000 after purchasing an additional 5,779,100 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its position in Baxter International by 40.4% in the 4th quarter. Russell Investments Group Ltd. now owns 1,745,709 shares of the medical instruments supplier’s stock worth $50,904,000 after purchasing an additional 502,370 shares during the last quarter. Institutional investors own 90.19% of the company’s stock.

Baxter International Stock Performance

NYSE BAX opened at $31.71 on Wednesday. The company has a current ratio of 1.43, a quick ratio of 1.09 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $16.27 billion, a price-to-earnings ratio of -24.77, a P/E/G ratio of 0.93 and a beta of 0.61. The firm’s 50 day simple moving average is $30.05 and its 200 day simple moving average is $31.39. Baxter International Inc. has a 1 year low of $26.25 and a 1 year high of $40.49.

Baxter International (NYSE:BAX) last posted its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.14. The business had revenue of $2.63 billion for the quarter, compared to analyst estimates of $2.59 billion. Baxter International had a negative net margin of 5.05% and a positive return on equity of 16.67%. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter last year, the business posted $0.65 EPS. As a group, research analysts expect that Baxter International Inc. will post 2.48 earnings per share for the current fiscal year.

Baxter International Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 1st. Shareholders of record on Friday, May 30th will be given a $0.17 dividend. The ex-dividend date is Friday, May 30th. This represents a $0.68 dividend on an annualized basis and a yield of 2.14%. Baxter International’s dividend payout ratio is currently -61.82%.

Analysts Set New Price Targets

Several research firms recently weighed in on BAX. JPMorgan Chase & Co. dropped their price objective on shares of Baxter International from $38.00 to $36.00 and set a “neutral” rating for the company in a research report on Friday, February 21st. Argus upgraded shares of Baxter International from a “hold” rating to a “buy” rating in a research report on Monday, February 24th. Barclays upped their target price on shares of Baxter International from $39.00 to $41.00 and gave the company an “overweight” rating in a research report on Monday, March 10th. Morgan Stanley dropped their target price on shares of Baxter International from $30.00 to $28.00 and set an “underweight” rating for the company in a research report on Monday, May 5th. Finally, The Goldman Sachs Group started coverage on shares of Baxter International in a research report on Wednesday, February 26th. They set a “buy” rating and a $42.00 target price for the company. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $37.25.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.